BRIEF-Tiziana Announces Reduction Of Side Effects Commonly Seen With Discontinuation Of GLP-1 Agonists With Nasal Anti-CD3

Reuters
10 Jan
BRIEF-Tiziana Announces Reduction Of Side Effects Commonly Seen With Discontinuation Of GLP-1 Agonists With Nasal Anti-CD3

Jan 10 (Reuters) - Tiziana Life Sciences Ltd TLSA.O:

  • TIZIANA ANNOUNCES REDUCTION OF SIDE EFFECTS COMMONLY SEEN WITH DISCONTINUATION OF GLP-1 AGONISTS WITH NASAL ANTI-CD3

  • TIZIANA LIFE SCIENCES LTD - GLP-1 DRUGS FACE LONG TERM TOLERABILITY ISSUES

  • TIZIANA LIFE SCIENCES LTD - FDA ALLOWS ADDITIONAL 20 PATIENTS IN FORALUMAB EXPANDED ACCESS PROGRAM

Source text: nGNX1JJ8Xz

Further company coverage: TLSA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10